Published: October 29, 2025 at 11:27 am
MedTech giant GSK has upgraded its 2025 guidance after solid growth across all divisions helped lift sales, profit and earnings.
For the three months to the 30th September, the pharmaceutical firm reported sales of £8.5 billion, up 7% at actual exchange rates (AER) and 8% at constant exchange rates (CER).
Total operating profit for the FTSE 100 constituent climbed to £2.59bn – more than doubling from last year.